DK0927192T3 - Modificerede aminosyrer, lægemidler indeholdende disse forbindelser og fremgangsmåder til deres fremstilling - Google Patents

Modificerede aminosyrer, lægemidler indeholdende disse forbindelser og fremgangsmåder til deres fremstilling

Info

Publication number
DK0927192T3
DK0927192T3 DK97938928T DK97938928T DK0927192T3 DK 0927192 T3 DK0927192 T3 DK 0927192T3 DK 97938928 T DK97938928 T DK 97938928T DK 97938928 T DK97938928 T DK 97938928T DK 0927192 T3 DK0927192 T3 DK 0927192T3
Authority
DK
Denmark
Prior art keywords
compounds
preparation
methods
amino acids
modified amino
Prior art date
Application number
DK97938928T
Other languages
Danish (da)
English (en)
Inventor
Klaus Rudolf
Wolfgang Eberlein
Wolfhard Engel
Helmut Pieper
Henri Doods
Gerhard Hallermayer
Michael Entzeroth
Wolfgang Wienen
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19636623A external-priority patent/DE19636623A1/de
Priority claimed from DE19720011A external-priority patent/DE19720011A1/de
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of DK0927192T3 publication Critical patent/DK0927192T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Addiction (AREA)
DK97938928T 1996-09-10 1997-09-08 Modificerede aminosyrer, lægemidler indeholdende disse forbindelser og fremgangsmåder til deres fremstilling DK0927192T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19636623A DE19636623A1 (de) 1996-09-10 1996-09-10 Abgewandelte Aminosäuren, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19720011A DE19720011A1 (de) 1997-05-14 1997-05-14 Abgewandelte Aminosäuren, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Hetstellung

Publications (1)

Publication Number Publication Date
DK0927192T3 true DK0927192T3 (da) 2004-09-13

Family

ID=26029200

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97938928T DK0927192T3 (da) 1996-09-10 1997-09-08 Modificerede aminosyrer, lægemidler indeholdende disse forbindelser og fremgangsmåder til deres fremstilling

Country Status (33)

Country Link
US (2) US6344449B1 (xx)
EP (2) EP0927192B1 (xx)
JP (2) JP3483893B2 (xx)
CN (1) CN1129605C (xx)
AR (1) AR009742A1 (xx)
AT (2) ATE402187T1 (xx)
AU (1) AU721035C (xx)
BG (1) BG64214B1 (xx)
BR (1) BR9712023A (xx)
CA (1) CA2262818A1 (xx)
CO (1) CO4910127A1 (xx)
CZ (1) CZ82399A3 (xx)
DE (2) DE59712953D1 (xx)
DK (1) DK0927192T3 (xx)
EA (1) EA004037B1 (xx)
EE (1) EE04375B1 (xx)
ES (2) ES2221691T3 (xx)
HK (1) HK1021192A1 (xx)
HR (1) HRP970481B1 (xx)
ID (1) ID21045A (xx)
IL (1) IL128118A0 (xx)
MY (1) MY140677A (xx)
NO (1) NO991130L (xx)
NZ (1) NZ334543A (xx)
PE (1) PE109698A1 (xx)
PT (1) PT927192E (xx)
RS (1) RS49791B (xx)
SA (1) SA97180668B1 (xx)
SK (1) SK285631B6 (xx)
TR (1) TR199900537T2 (xx)
TW (2) TW477792B (xx)
UY (1) UY24704A1 (xx)
WO (1) WO1998011128A1 (xx)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025372A (en) * 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
EP1117662A1 (en) * 1998-09-30 2001-07-25 Merck Sharp & Dohme Limited Benzimidazolinyl piperidines as cgrp ligands
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
DE19911039A1 (de) * 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6387932B1 (en) 1999-06-25 2002-05-14 Merck & Co., Inc. Somatostatin agonists
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
DE19937304C2 (de) * 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
DE19952147A1 (de) * 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19952146A1 (de) 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
YU32702A (sh) 1999-11-04 2005-06-10 Ortho-Mcneil Pharmaceutical Inc. Nepeptidni supstituisani benzotiazepini kao antagonisti vazopresina
DE19963868A1 (de) * 1999-12-30 2001-07-12 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DK1787984T3 (en) 2000-03-06 2017-01-30 Acadia Pharm Inc AZACYCLIC COMPOUNDS FOR USING THE TREATMENT OF SEROTON-RELATED DISEASES
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
US6653478B2 (en) 2000-10-27 2003-11-25 Ortho-Mcneil Pharmaceutical, Inc. Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators
NZ527026A (en) * 2001-03-01 2006-01-27 Emisphere Tech Inc Compounds and compositions for delivering active agents
GB0108876D0 (en) * 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
PL367310A1 (en) * 2001-04-18 2005-02-21 Euro-Celtique, S.A. Nociceptin analogs
JP3857270B2 (ja) 2001-07-02 2006-12-13 アストラゼネカ・アクチエボラーグ ケモカイン受容体活性のモジュレーターとして有用なピペリジン誘導体
US6977264B2 (en) * 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US20030181462A1 (en) * 2001-08-17 2003-09-25 Boehringer Ingelheim Pharma Kg Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
DE10139410A1 (de) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
CN101050215A (zh) 2001-12-28 2007-10-10 阿卡蒂亚药品公司 作为单胺受体调节剂的螺氮杂环化合物
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
US6900317B2 (en) * 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
US20040014679A1 (en) * 2002-02-20 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co., Kg Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
US7842808B2 (en) * 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
MXPA04011960A (es) * 2002-06-05 2005-03-31 Squibb Bristol Myers Co Antagonistas de receptores de peptidos relacionados con el gen de calcitonina.
US7220862B2 (en) * 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US20040076587A1 (en) * 2002-06-19 2004-04-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for intranasal administration containing a CGRP antagonist
DE10227294A1 (de) * 2002-06-19 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Zubereitungen zur intranasalen Applikation ausgewählter, von Aminosäuren abgeleiteter CGRP-Antagonisten sowie Verfahren zu deren Herstellung
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
KR20050008846A (ko) 2002-06-24 2005-01-21 아카디아 파마슈티칼스 인코포레이티드 세로토닌 수용체 제제로서의 ｎ-치환된 피페리딘 유도체
GB0218326D0 (en) * 2002-08-07 2002-09-11 Glaxo Group Ltd Compounds
JP2006505531A (ja) * 2002-09-11 2006-02-16 メルク　エンド　カムパニー　インコーポレーテッド メラノコルチン−４受容体作働薬としてのピペラジン尿素誘導体
US7595312B2 (en) * 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10300973A1 (de) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
KR101095939B1 (ko) 2003-01-16 2011-12-19 아카디아 파마슈티칼스 인코포레이티드 신경퇴행성 질환에 대한 치료제로서 선택적 세로토닌2ａ／2ｃ 리셉터 역작용제
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
US20050042179A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
US20050043247A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
US20050042178A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
US20050042180A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Powder formulation containing the CGRP antagonist 1 [N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2 (1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin, process for preparing and the use thereof as inhalation powder
US20050065094A1 (en) 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
CA2545644C (en) * 2003-11-12 2011-11-01 Lg Life Sciences Ltd. Melanocortin receptor agonists
US7855207B2 (en) 2003-11-20 2010-12-21 Janssen Pharmaceutica, Nv 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors
EA011211B1 (ru) 2003-11-20 2009-02-27 Янссен Фармацевтика Н. В. 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
RS20060382A (xx) 2003-12-05 2008-09-29 Bristol-Myers Squibb Company, Antagonisti receptora za peptid povezan sa genom za kalcitonin
AR046787A1 (es) 2003-12-05 2005-12-21 Bristol Myers Squibb Co Agentes antimigrana heterociclicos
NZ547193A (en) * 2003-12-05 2010-03-26 Janssen Pharmaceutica Nv 6-Substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
US20050192230A1 (en) * 2004-02-12 2005-09-01 Boehringer Ingelheim International Gambh Process for preparing 1- [N²-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
DE102004006893A1 (de) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von 1[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US7547694B2 (en) * 2004-04-15 2009-06-16 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018794A1 (de) * 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018795A1 (de) * 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20050282857A1 (en) * 2004-04-15 2005-12-22 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018796A1 (de) * 2004-04-15 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20050233980A1 (en) * 2004-04-20 2005-10-20 Boehringer Ingelheim International Gmbh CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine
DE102004019492A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7696195B2 (en) * 2004-04-22 2010-04-13 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
MXPA06014542A (es) 2004-06-30 2007-03-23 Janssen Pharmaceutica Nv Derivados de ftalazina como inhibidores de poli(adp-ribosa) polimerasa-i.
BRPI0512938A (pt) 2004-06-30 2008-04-15 Janssen Pharmaceutica Nv derivados da quinazolinediona como inibidores parp
UA85593C2 (xx) * 2004-06-30 2009-02-10 Янссен Фармацевтика Н.В. Похідні хіназолінону як інгібітори parp$производные хиназолинона как ингибиторы parp
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
US7732615B2 (en) 2004-09-27 2010-06-08 Acadia Pharmaceuticals Inc. N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
DE102004063755A1 (de) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
DE102004063753A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE102004063752A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
EP1770091A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7491717B2 (en) * 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7439237B2 (en) 2005-04-15 2008-10-21 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
AU2006270548A1 (en) 2005-07-21 2007-01-25 Astrazeneca Ab Novel piperidine derivatives
DE102005038831A1 (de) * 2005-08-17 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7834007B2 (en) * 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
DE102005042828A1 (de) * 2005-09-09 2007-03-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGPR-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770087A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770086A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102005050892A1 (de) * 2005-10-21 2007-04-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
PL1957106T5 (pl) 2005-11-14 2019-11-29 Teva Pharmaceuticals Int Gmbh Przeciwciała antagonistyczne skierowane przeciw peptydowi związanemu z genem kalcytoniny i sposoby je wykorzystujące
JP2009515972A (ja) * 2005-11-18 2009-04-16 メルク エンド カムパニー インコーポレーテッド スピロラクタムアリールｃｇｒｐ受容体アンタゴニスト
US7601844B2 (en) * 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
WO2007115805A2 (en) * 2006-04-05 2007-10-18 European Molecular Biology Laboratory (Embl) Aurora kinase inhibitors
DE102006017827A1 (de) * 2006-04-13 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue kristalline Verbindungen
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
WO2008079945A2 (en) * 2006-12-20 2008-07-03 University Of South Florida Rock inhibitors and uses thereof
JP5545955B2 (ja) 2007-03-08 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体
AU2008228833B9 (en) 2007-03-19 2013-10-24 Acadia Pharmaceuticals Inc. Combinations of 5-HT2A inverse agonists and antagonists with antipsychotics
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
WO2009053373A1 (en) 2007-10-26 2009-04-30 Janssen Pharmaceutica Nv Quinolinone derivatives as parp inhibitors
MX2010009722A (es) 2008-03-04 2010-09-30 Pfizer Ltd Procedimiento de tratamiento del dolor cronico.
EP2265288B1 (en) 2008-03-04 2016-05-11 Labrys Biologics Inc. Methods of treating inflammatory pain
JP5492183B2 (ja) 2008-03-27 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐおよびチューブリン重合阻害剤としてのテトラヒドロフェナントリジノンおよびテトラヒドロシクロペンタキノリノン
ES2367760T3 (es) 2008-03-27 2011-11-08 Janssen Pharmaceutica, N.V. Derivados de quinazolinona como inhibidores de la polimerización de la tubulina.
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
CN107441487B (zh) 2009-08-28 2021-09-14 泰华制药国际有限公司 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
BR122022012930B1 (pt) 2011-05-20 2023-10-10 H. Lundbeck A/S Anticorpo anti-cgrp ou fragmento de anticorpo anti-cgrp, sequências de ácido nucleico, vetor, célula cultivada ou recombinante, composição farmacêutica e uso do referido anticorpo ou fragmento de anticorpo
TWI609888B (zh) 2011-05-20 2018-01-01 艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）或抗降血鈣素基因相關胜肽受器（ａｎｔｉ－ｃｇｒｐ－ｒ）抗體或抗體片段治療或預防慢性及急性型腹瀉之用途
WO2012162257A2 (en) 2011-05-20 2012-11-29 Alderbio Holdings Llc Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
JP5988087B2 (ja) * 2012-06-07 2016-09-07 Dic株式会社 化合物の製造方法
WO2014102592A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
PT3119431T (pt) 2014-03-21 2024-04-16 Teva Pharmaceuticals Int Gmbh Anticorpos antagonistas dirigidos contra o peptídeo relacionado com o gene da calcitonina e métodos de utilização dos mesmos
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP3325444B1 (en) 2015-07-20 2021-07-07 Acadia Pharmaceuticals Inc. Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
SG10201913032TA (en) 2016-09-23 2020-02-27 Teva Pharmaceuticals Int Gmbh Treating refractory migraine
US11464768B2 (en) 2016-12-20 2022-10-11 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis
EP3615028A1 (en) 2017-04-28 2020-03-04 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
TWI839435B (zh) 2019-01-08 2024-04-21 丹麥商Ｈ．朗德貝克公司 使用抗cgrp 抗體急性治療和快速治療頭痛
AU2022230300A1 (en) 2021-03-02 2023-09-21 Cgrp Diagnostics Gmbh Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
WO2024100171A1 (en) 2022-11-11 2024-05-16 Boehringer Ingelheim International Gmbh Olcegepant for treating sepsis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0201741B1 (en) * 1985-04-16 1991-07-31 Suntory Limited Dipeptide derivatives, processes for preparing them, pharmaceutical composition and use
CA1320734C (en) 1986-02-04 1993-07-27 Suntory Limited Pyrrolidineamide derivative of acylamino acid and pharmaceutical composition containing the same
US4873253A (en) * 1987-03-30 1989-10-10 Shosuke Okamoto Phenylalanine derivative and proteinase inhibitor
EP0298135A1 (en) * 1987-03-30 1989-01-11 Shosuke Okamoto Phenylalanine derivative and proteinase inhibitor
US5153226A (en) * 1989-08-31 1992-10-06 Warner-Lambert Company Acat inhibitors for treating hypocholesterolemia
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
CA2137832C (en) * 1992-06-12 2000-09-26 Dennis J. Hoover Inhibitors of angiotensin i chymase(s) including human heart chymase
CA2166075A1 (en) * 1993-06-30 1995-01-12 Yoshiharu Ikeda Novel dipiperidine derivative
AU7953194A (en) * 1994-08-16 1996-03-07 Human Genome Sciences, Inc. Calcitonin receptor
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
FR2729855A1 (fr) * 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue

Also Published As

Publication number Publication date
UY24704A1 (es) 2000-09-29
IL128118A0 (en) 1999-11-30
WO1998011128A1 (de) 1998-03-19
MY140677A (en) 2010-01-15
EP0927192A1 (de) 1999-07-07
ATE402187T1 (de) 2008-08-15
JP2000505100A (ja) 2000-04-25
JP2003300959A (ja) 2003-10-21
YU37297A (xx) 2002-08-12
HRP970481B1 (en) 2003-10-31
NO991130L (no) 1999-05-05
RS49791B (sr) 2008-06-05
EA199900278A1 (ru) 1999-10-28
BG103250A (en) 2000-05-31
AU721035C (en) 2004-09-02
ATE266673T1 (de) 2004-05-15
PT927192E (pt) 2004-09-30
US20010036946A1 (en) 2001-11-01
HRP970481A2 (en) 1998-08-31
EP1440976B1 (de) 2008-07-23
BG64214B1 (bg) 2004-05-31
CA2262818A1 (en) 1998-03-19
CN1129605C (zh) 2003-12-03
ES2314305T3 (es) 2009-03-16
ID21045A (id) 1999-04-08
SK285631B6 (sk) 2007-05-03
US6344449B1 (en) 2002-02-05
PE109698A1 (es) 1999-02-01
NO991130D0 (no) 1999-03-09
DE59712953D1 (de) 2008-09-04
CO4910127A1 (es) 2000-04-24
SK29799A3 (en) 2000-03-13
AU721035B2 (en) 2000-06-22
AR009742A1 (es) 2000-05-03
CN1230196A (zh) 1999-09-29
EA004037B1 (ru) 2003-12-25
TW477792B (en) 2002-03-01
TR199900537T2 (xx) 1999-07-21
EE04375B1 (et) 2004-10-15
EP0927192B1 (de) 2004-05-12
JP3483893B2 (ja) 2004-01-06
SA97180668B1 (ar) 2006-08-14
TW498076B (en) 2002-08-11
NZ334543A (en) 2000-06-23
BR9712023A (pt) 1999-08-31
AU4119697A (en) 1998-04-02
DE59711622D1 (de) 2004-06-17
ES2221691T3 (es) 2005-01-01
EE9900115A (et) 1999-10-15
CZ82399A3 (cs) 1999-06-16
EP1440976A1 (de) 2004-07-28
HK1021192A1 (en) 2000-06-02

Similar Documents

Publication Publication Date Title
DK0927192T3 (da) Modificerede aminosyrer, lægemidler indeholdende disse forbindelser og fremgangsmåder til deres fremstilling
DK1156049T3 (da) Substituerede heterocykliske forbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
DK1112251T3 (da) Azetidinderivater, deres fremstilling og medikamenter indeholdende disse derivater
DK1032555T3 (da) Cykliske aminosyrer og derivater deraf, som er anvendelige som lægemidler
DK0811006T3 (da) Benzopyranholdige forbindelser og fremgangsmåde til deres anvendelse
DK0739898T3 (da) Phosphononmoneosternukleinsyrer, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK0906029T3 (da) Isoflavonberiget sojaproteinprodukt og fremgangsmåde til fremstilling heraf
NO20012158D0 (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
NO991815D0 (no) Oksadiazoler, fremgangsmÕter for deres fremstilling og deres anvendelse som medikamenter
DK0729956T3 (da) Benzothi9phenforbindelser, emllemprodukter, præparater og fremgangsmåder
DK199900554A (da) Paroxetinsalte, fremgangsmåde til fremstilling deraf, farmaceutiske præparater omfattende disse og anvendelser deraf
NO20003067L (no) Antipicornavirus-forbindelser og fremgangsmÕter for deres anvendelse og fremstilling
DK0918059T3 (da) Susbstituerede imidazolidinderivater, deres fremstilling og anvendelse samt farmaceutiske præparater indeholdende disse derivater
DK1015444T3 (da) Pyrimidinderivater og fremgangsmåder til fremstilling deraf
DK0885204T3 (da) Nye arylglycinamidderivater, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende disse forbindelser
NO932120D0 (no) Bifenylderivater, legemidler inneholdende disse, og fremgangsmaate for deres fremstilling
NO985262D0 (no) Fosfonsyresubstituerte benzazepinon-N-edikksyrederivater, fremgangsmÕte for deres fremstilling og legemidler inneholdende slike
DK0773984T3 (da) Enzymholdig granuleret substans og fremgangsmåde til fremstilling heraf
NO984309D0 (no) Nye imidazolidinderivater, deres fremstilling, deres anvendelse og farmas°ytiske preparater inneholdende disse
DK1003383T4 (da) Smagsforstærkende N-ethyl-p-menthan-3-carboxamidindeholdende forbindelser og fremgangsmåde til fremstilling og anvendelse deraf
DK1117661T3 (da) Propanolaminderivater substitueret med heterocycliske grupper, fremgangsmåde til deres fremstilling, farmaceutiske præparater indeholdende disse forbindelser og deres anvendelse
DK0838469T3 (da) 10,13,15-trioxatricyclo(9.2.1 9.6)-pentadecanon-derivater, fremgangsmåde til deres fremstilling og lægemidler indeholdende disse forbindelser
DK1015433T3 (da) Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-oler, fremgangsmåder til fremstilling af disse og deres anvendelse som lægemidler
NO932636L (no) Benzimidazoler, medikamenter inneholdende disse forbindelser, og fremgangsmaate for deres fremstilling
DK0791591T3 (da) Benzothiophener, formuleringer indeholdende samme og fremgangsmåder til deres fremstilling